00:35 , Jul 13, 2019 |  BioCentury  |  Product Development

Why Merck is in infectious disease for the long haul

Merck is bucking the trend of its biopharma peers by continuing to invest in and build its infectious disease pipeline. With new regulatory pathways in play and novel funding mechanisms for antibiotics starting to take...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

AureoGen Biosciences, Merck deal

AureoGen granted Merck exclusive rights to develop and commercialize preclinical derivatives of aureobasidin A to treat infectious disease, including systemic fungal infections. Merck will also have exclusive rights to additional derivatives generated using AureoGen’s chemistry...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Company News

AureoGen Biosciences, Takara Bio deal

AureoGen received non-exclusive rights to develop and commercialize Takara’s antifungal compound aureobasidin A and related antibiotics. AureoGen also received rights to Aureobasidium pullulans, the organism that produces the cyclic peptide. All licensed compounds are in...